Neutrophil elastase (ELANE) pathway - N17350 acts as a direct

Class

Recombinant engineered porcine pancreatic elastase (protease-based intratumoral immunotherapy)

Pathway

Activates neutrophil elastase (ELANE)-mediated tumor cell killing after intratumoral injection

Notes

original target text: Neutrophil elastase (ELANE) pathway - N17350 acts as a direct protease/enzyme therapeutic rather than a receptor-binding inhibitor

Neutrophil elastase is a serine protease normally produced by neutrophils, a type of white blood cell that forms part of the innate immune system. Stored inside cellular granules, it is released during inflammation to break down bacterial proteins, connective tissue, and other biological substrates. This mechanism repurposes elastase-like enzymatic activity as a direct anticancer tool, rather than pursuing the more common pharmacological strategy of inhibiting elastase to limit tissue damage in inflammatory disease. The therapeutic is an engineered protease enzyme, delivered by direct injection into a tumor, where it acts by physically degrading proteins on cancer cell membranes and within the surrounding tumor tissue, causing cell disruption and lysis independent of any receptor-binding step. This qualifies as a form of intratumoral immunotherapy: localized enzymatic destruction of tumor tissue can also release tumor antigens and break down physical barriers that shield tumors from immune surveillance, potentially amplifying an anti-tumor immune response. Because enzymatic activity is confined to the injection site, this approach seeks a wide therapeutic window relative to the toxicity that would result from systemic protease exposure. This class of mechanism is broadly relevant in solid tumor settings where localized tumor destruction combined with immune activation are therapeutic goals, particularly for lesions accessible to direct injection.